Evidence map›Paper›PMID 27605245›Full record

ArticleArthritis research & therapy2016

Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis.

Linda Johansson, Natalia Sherina, Nastya Kharlamova, Barbara Potempa, Barbro Larsson, Lena Israelsson, Jan Potempa, Solbritt Rantapää-Dahlqvist, Karin Lundberg

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. RMD open · 2025
    Article
  13. Review
  14. Review
  15. Neutrophils in Inflammatory Bone Diseases.Current osteoporosis reports · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Linda JohanssonPublic Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden.
Natalia SherinaRheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Nastya KharlamovaRheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Barbara PotempaDepartment of Oral Immunology and Infectious Diseases, University of Louisville, School of Dentistry, Louisville, KY, USA.
Barbro LarssonRheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Lena IsraelssonRheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Jan PotempaDepartment of Oral Immunology and Infectious Diseases, University of Louisville, School of Dentistry, Louisville, KY, USA.
Solbritt Rantapää-DahlqvistPublic Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden. solbritt.rantapaa.dahlqvist@umu.se.
Karin LundbergRheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEUmeå University · SEJagiellonian University · PLUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe periodontal pathogen Porphyromonas gingivalis is hypothesized to be important in rheumatoid arthritis (RA) aetiology by inducing production of anti-citrullinated protein antibodies (ACPA). We have shown that ACPA precede RA onset by years, and that anti-P. gingivalis antibody levels are elevated in RA patients. The aim of this study was to investigate whether anti-P. gingivalis antibodies pre-date symptom onset and ACPA production.

methodsA case-control study (251 cases, 198 controls) was performed within the Biobank of Northern Sweden. Cases had donated blood samples (n = 422) before the onset of RA symptoms by 5.2 (6.2) years (median (interquartile range)). Blood was also collected from 192 RA patients following diagnosis. Antibodies against P. gingivalis virulence factor arginine gingipainB (RgpB), and a citrullinated peptide (CPP3) derived from the P. gingivalis peptidylarginine deiminase enzyme, were analysed by ELISA.

resultsAnti-RgpB IgG levels were significantly increased in pre-symptomatic individuals (mean ± SEM; 152.7 ± 14.8 AU/ml) and in RA patients (114.4 ± 16.9 AU/ml), compared with controls (p < 0.001). Anti-CPP3 antibodies were detected in 5 % of pre-symptomatic individuals and in 8 % of RA patients, with elevated levels in both subsets (4.33 ± 0.59 and 9.29 ± 1.81 AU/ml, respectively) compared with controls (p < 0.001). Anti-CPP3 antibodies followed the ACPA response, with increasing concentrations over time, whilst anti-RgpB antibodies were elevated and stable in the pre-symptomatic individuals with a trend towards lower levels after RA diagnosis.

conclusionsAnti-P. gingivalis antibody concentrations were significantly increased in RA patients compared with controls, and were detectable years before onset of symptoms of RA, supporting an aetiological role for P. gingivalis in the development of RA.

Indexed as

Adhesins, BacterialAdultAgedAntibodies, BacterialAntigens, BacterialArthritis, RheumatoidBacteroidaceae InfectionsCase-Control StudiesCysteine EndopeptidasesEnzyme-Linked Immunosorbent AssayFemaleGingipain Cysteine EndopeptidasesHumansMaleMiddle AgedOdds RatioAdhesins, BacterialAntibodies, BacterialAntigens, Bacterialcyclic citrullinated peptideCysteine EndopeptidasesGingipain Cysteine EndopeptidasesPeptides, CyclicAntibodiesAnti-citrullinated protein/peptide antibodiesArginine gingipainBCitrullinated peptidePorphyromonas gingivalisPredating onsetRheumatoid arthritis

Identifiers

PMID27605245
PMCPMC5015325
OpenAlexW2516363365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.